The stock of BELLUS Health Inc. (BLU) gained significantly in the Pre-market after the company announced positive topline results from its trials for the treatment of Refractory Chronic Cough. At the last close the stock gained more than 48% from the previously closed value to reach at $8.3 in the on Monday.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Reason of the stock gain:
Today in a press release BELLUS Health Inc. (BLU) announced the positive results from its Phase 2b SOOTHE trials of BLU 5937. These trials were conducted for the treatment of Refractory Chronic Cough (RCC).
The data showed that 12.5 mg BID dose resulted in the cough at an average of 21% in a time period of 24 hours. The dose of BID was kept in between 12.5-50 mg. The patients who took part in the trials showed placebo-adjusted reduction of 34% in 24 hour timeperiod.
The taste related issues were found in some participants but they were of no concern as it was for a limited time period and in a few patients. The taste alteration was found in patients that were given a dose of 12.5 mg BID, 50 mg BID and 200 mg BID. They showed a taste alteration of 4.8%, 6.5% and 4.8% respectively. But the adverse effect of BLU-5937 taste loss was not permanent and this did not affect the trial’s progress.
The Company is looking forward to the end of Phase 2 meeting with the FDA that is expected to take place in the second quarter of 2022 to discuss the Phase-3 program which is expected to begin in 2022.
Effect on the stock:
After this major development by the company, is stock surged significantly in the last session. This new development in the treatment of RCC is expected to bring in more revenue for the company in the next year.
Conclusion:
The company is looking forward to the meeting with FDA about the phase 2 trials and the beginning of phase 3 program. The stock of the company is getting the attention of the investors after this press release.
